Wall Street is even more bullish with the post-profit Palantir
3 minutes ago
Shares of Palantir Technologies (PLTR) are on a strong upward trajectory, as multiple analysts from Wall Street have increased their price targets following the company’s impressive revenue report.
According to Bank of America analysts, Palantir’s latest quarterly revenues exceeded $1 billion, marking a 48% year-over-year increase, with an impressive margin of 46% and a “40 Rule” score of 94%. In light of these results, they maintained a “buy” rating on the stock, raising the price target from $150 to $180.
Similarly, Morgan Stanley has upped the price target for Palantir from $88 to $155, citing “significant margin expansion” and referring to the company as a “clear AI winner.”
On another note, Deutsche Bank’s analysts have also increased their stock valuation, changing their rating from “sell” to “hold,” and doubling their price target from $80 to $160.
Palantir’s shares experienced a nearly 7% increase, reaching around $171 in midday trading, after previously hitting a record high of $176 earlier in the day.
The top dives after a disappointing painkiller exam
1 hour 25 minutes ago
Shares of Vertex Pharmaceuticals (VRTX) plummeted recently, reflecting a broader concern within the pharmaceutical industry following a study that indicated unsuccessful results for new pain medications.
The company stated that its Phase 2 trial of VX-993 failed to show a statistically significant improvement in pain intensity compared to a placebo on the primary endpoint of a time-weighted total in the first 48 hours.
Carmen Bozic, the Chief Medical Officer, noted that the findings suggest the drug should not proceed as a monotherapy for acute pain, indicating that it may not outperform other existing treatments. This trial followed Vertex’s previous work on a NAV1.8 inhibitor, Journavx, which is FDA-approved.
Interestingly, Vertex’s second-quarter results were strong, with adjusted earnings per share at $4.52, reflecting a 12% increase from last year, along with total revenues of $2.96 billion, both surpassing analyst expectations. Much of this revenue came from its cystic fibrosis treatment.
However, following the study news, Vertex’s shares dropped by 17%, pushing the stock into negative territory for the year.
Palantir soared to AI fuel revenue beats, boosting the outlook
2 hours 19 minutes ago
Palantir (PLTR) experienced a notable rise in early trading after announcing second-quarter revenues that significantly exceeded analyst projections, signaling strong demand for its AI platform.
The data analytics company reported adjusted earnings of 16 cents, achieving record revenues of $1 billion—a 48% jump compared to the previous year.
CEO Alex Carp referred to the quarter as “stolen,” emphasizing the remarkable impact of AI leverage.
He also highlighted that Palantir’s commercial business has nearly doubled in the past year, with notable growth of 68% for U.S. businesses.
Looking ahead, Palantir projected revenues between $3.89 billion and $3.9 billion, compared to previous figures of $1.08 billion, along with expectations for an increase to between $4.14 billion and $4.15 billion, all notably higher than analysts’ estimates.
Palantir’s shares reached all-time highs, climbing 9% in recent trading, reflecting a remarkable 130% increase since its launch in 2025.
The amount of AMD to move after revenue
3 hours 28 minutes ago
Advanced Micro Devices (AMD) is expected to release its second-quarter results soon, and traders are anticipating a significant movement from the chipmaker’s stocks.
Current option pricing indicates that traders foresee stocks moving over 7% from nearly $177 by the end of this week. A significant surge could push prices above $190, similar to a peak observed last March, while a decline could see stocks drop to around $163. So far this year, AMD has achieved over a 45% increase.
After its first-quarter report, AMD shares rose nearly 2%, but they dropped 6% and 10% respectively following the two prior reports. In May, the company surpassed estimates and provided revenue forecasts that exceeded analyst consensus.
Chipmakers are generally expected to report gains in second-quarter sales, despite warnings about more stringent chip export restrictions to China affecting AMD, alongside a projected dip in profits.
Wall Street analysts are divided on the outlook, though reports suggest AMD plans to resume exports of MI308 chips to China, previously approved by U.S. authorities— a more optimistic sign overall.
In recent pre-market trading, AMD shares increased by 1%.
Major index futures refer to slightly higher opens
4 hours 13 minutes ago
Futures linked to the Dow Jones industrial average showed slight increases.
S&P 500 futures were up by 0.2%.
Meanwhile, Nasdaq 100 futures rose by 0.4%.
